论文部分内容阅读
Atrisl fibrillation (AF) increases the risk of thromboembolic complications, including stroke and extracranial systemic embolic events, which call for therapeutic prophylaxis with oral anticoagulation (OAC). It is estimated that about 20％ to 40％ of patients with AF also present with coronary artery disease (CAD), a sizeable proportion of whom requires revascularization using percutaneous coronary intervention(PCI)and stent implantation. Such patients need dual antiplatelet therapy (dual antiplatelet therapy,DAPT)to prevent the risk of stent thrombosis and additional thrombotic ischemic events.